Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
artemisia annua pollen allergen extract
- Development stage
- Phase 4
- Lead developer
- Wolwo Biotech
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Sublingual
01
Overview
Artemisia annua sublingual allergen drops are a form of sublingual immunotherapy (SLIT) developed for the treatment of seasonal allergic rhinitis induced by *Artemisia* (wormwood) pollen. The product consists of standardized allergen extracts derived from *Artemisia annua* pollen, which are administered sublingually to induce immunological tolerance. The mechanism involves modulating the immune system to reduce hypersensitivity, primarily by promoting the expansion of regulatory T cells (Tregs), shifting the immune response from a Th2-mediated allergic profile to a Th1-mediated profile, and stimulating the production of allergen-specific IgG4 antibodies. These IgG4 antibodies act as blocking antibodies that compete with IgE for allergen binding, thereby inhibiting mast cell and basophil degranulation. The drug was approved in China in 2021, and clinical studies, such as those conducted by Hohhot First Hospital, continue to evaluate its efficacy in combination with other agents like probiotics.
- Brand names
- Artemisia Annua Pollen Allergen Sublingual Drops
- Other names
- Artemisia annua sublingual allergen dropsArtemisia annua SLITArtemisia annua pollen allergen sublingual drops
02
Targets
TCR (T cell antigen receptor complex)sIgG4 (Allergen-specific immunoglobulin G4)IgE (Immunoglobulin E)
Beyond the preview
Go deeper on artemisia annua pollen allergen extract.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on artemisia annua pollen allergen extract.